<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="de-escalating therapy by switching to immunomodulatory DMTs, such as interferon-beta," exact="glatiramer acetate" post="or teriflunomide, or interrupting dosing of DMTs to wait"/>
 <result pre="beneficial in the case of COVID-19 Very low Glatiramer acetate" exact="Copaxone" post="Immunomodulatoy (not immunosuppressive), pleitropic immune effects Moderate Maintenance immunomodulatoy"/>
 <result pre="that may be beneficial in the case of COVID-19 Low" exact="Dimethyl fumarate" post="Tecfidera Pleotropic, NRF2 activation, downregulation of NFÎšÎ² Moderate (2nd-3rd-line)"/>
 <result pre="shedding. Paradoxically S1P modulators may reduce the severity of COVID-19;" exact="fingolimod" post="is currently being trialed. Intermediate Anti-CD20 Ocrelizumab (Ocrevus), Ofatumumab."/>
 <result pre="other anti-CD20 therapies may result in prolonged viral shedding. Intermediate" exact="Cladribine" post="Mavenclad Deoxyadenosine (purine) analogue, adenosine deaminase inhibitor, selective T"/>
 <result pre="therapies may result in prolonged viral shedding. Intermediate Cladribine Mavenclad" exact="Deoxyadenosine" post="(purine) analogue, adenosine deaminase inhibitor, selective T and B"/>
 <result pre="in prolonged viral shedding. Intermediate Cladribine Mavenclad Deoxyadenosine (purine) analogue," exact="adenosine" post="deaminase inhibitor, selective T and B cell depletion High"/>
 <result pre="Yes, intermittent Theoretical risk that in the immune depletion phase" exact="cladribine" post="may result in prolonged viral shedding. High* Mitoxantrone Novatrone"/>
 <result pre="depletion phase cladribine may result in prolonged viral shedding. High*" exact="Mitoxantrone" post="Novatrone Immune depleter (topoisomerase inhibitor) Very high IRT (non-selective)"/>
 <result pre="Yes, intermittent Theoretical risk that in the immune depletion phase" exact="mitoxantrone" post="may result in prolonged viral shedding. High* Alemtuzumab Lemtrada"/>
 <result pre="the treatment, i.e. haematopoietic stem cell transplantation (HSCT), alemtuzumab (Lemtrada)," exact="mitoxantrone" post="(Novantrone) and cladribine (Mavenclad). After immune reconstitution, once the"/>
 <result pre="haematopoietic stem cell transplantation (HSCT), alemtuzumab (Lemtrada), mitoxantrone (Novantrone) and" exact="cladribine" post="(Mavenclad). After immune reconstitution, once the total lymphocyte counts"/>
 <result pre="comorbidities and are relatively young. Of the immune reconstitution therapies," exact="cladribine" post="(Mavenclad) is classed as intermediate risk, because it is"/>
 <result pre="urinary tract infections and cellulitis). We therefore feel that both" exact="cladribine" post="and anti-CD20 therapies are relatively safe to use during"/>
 <result pre="a problem dealing with community acquired viral infections. Patients on" exact="fingolimod" post="who are exposed to and acquire exotic viral infections"/>
 <result pre="virus cleared the virus without complications similar to those on" exact="fingolimod" post="(FragosoÂ etÂ al., 2016b). Clearly, any decision to start"/>
 <result pre="recommend continuing the current DMT specifically with: -First-line DMTs (beta-interferons," exact="glatiramer acetate," post="teriflunomide or dimethyl fumarate). These DMTs can be prescribed"/>
 <result pre="and hand sanitizing (particularly for patients on fingolimod, alemtuzumab, ocrelizumab," exact="cladribine" post="or rituximab). -If possible, work from home. -Good personal"/>
 <result pre="coronavirus OC43J. Virol.7319993338335010074188 CookS.VermerschP.ComiG.GiovannoniG.RammohanK.RieckmannP.SÃ¸rensenP.S.HamlettA.MiretM.WeinerJ.VigliettaV.MuschB.GreenbergS.J.collab: CLARITY Study GroupSafety and tolerability of" exact="cladribine" post="tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating"/>
 <result pre="Dis.57201384985223728144 FragosoY.D.GamaP.D.daGomesS.KhouriJ.M.N.MattaA.P.daC.Fernanda MendesM.StellaC.R.A.V.Dengue fever in patients with multiple sclerosis taking" exact="fingolimod" post="or natalizumabMult. Scler. Relat. Disord.62016646527063625 FragosoY.D.GamaP.D.daGomesS.KhouriJ.M.N.MattaA.P.daC.Fernanda MendesM.StellaC.R.A.V.Dengue fever in"/>
 <result pre="Disord.62016646527063625 FragosoY.D.GamaP.D.daGomesS.KhouriJ.M.N.MattaA.P.daC.Fernanda MendesM.StellaC.R.A.V.Dengue fever in patients with multiple sclerosis taking" exact="fingolimod" post="or natalizumabMult. Scler. Relat. Disord.62016646527063625 FrancisG.KapposL.O'ConnorP.CollinsW.TangD.MercierF.CohenJ.A.Temporal profile of lymphocyte"/>
 <result pre="FrancisG.KapposL.O'ConnorP.CollinsW.TangD.MercierF.CohenJ.A.Temporal profile of lymphocyte counts and relationship with infections with" exact="fingolimod" post="therapyMult. Scler.20201447148023950550 GhoshS.GoldinE.GordonF.H.MalchowH.A.Rask-MadsenJ.RutgeertsP.VyhnÃ¡lekP.ZÃ¡dorovÃ¡Z.PalmerT.DonoghueS.collab: Natalizumab Pan-European Study GroupNatalizumab for active"/>
 <result pre="treatment of autoimmune and inflammatory diseasesPharmacol. Res.2019104170 StuveO.Soelberg SoerensenP.LeistT.GiovannoniG.HyvertY.DamianD.DangondF.BoschertU.Effects of" exact="cladribine" post="tablets on lymphocyte subsets in patients with multiple sclerosis:"/>
</results>
